Oregon Public Employees Retirement Fund Raises Position in Boston Scientific Corporation $BSX

Oregon Public Employees Retirement Fund lifted its position in shares of Boston Scientific Corporation (NYSE:BSX) by 0.9% during the second quarter, HoldingsChannel reports. The fund owned 127,839 shares of the medical equipment provider’s stock after acquiring an additional 1,200 shares during the quarter. Oregon Public Employees Retirement Fund’s holdings in Boston Scientific were worth $13,731,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in Boston Scientific by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 134,588,729 shares of the medical equipment provider’s stock worth $13,577,311,000 after purchasing an additional 1,697,945 shares during the period. Invesco Ltd. lifted its holdings in shares of Boston Scientific by 5.3% in the 1st quarter. Invesco Ltd. now owns 16,624,940 shares of the medical equipment provider’s stock valued at $1,677,124,000 after buying an additional 834,274 shares during the period. Goldman Sachs Group Inc. boosted its stake in shares of Boston Scientific by 10.8% in the first quarter. Goldman Sachs Group Inc. now owns 14,143,332 shares of the medical equipment provider’s stock valued at $1,426,779,000 after buying an additional 1,383,524 shares in the last quarter. Amundi grew its holdings in Boston Scientific by 2.6% during the first quarter. Amundi now owns 12,308,715 shares of the medical equipment provider’s stock worth $1,212,408,000 after acquiring an additional 311,034 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Boston Scientific by 4.2% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 11,299,942 shares of the medical equipment provider’s stock worth $1,139,938,000 after acquiring an additional 460,580 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have issued reports on BSX shares. Leerink Partnrs upgraded Boston Scientific to a “strong-buy” rating in a research report on Monday, June 16th. Robert W. Baird increased their price target on shares of Boston Scientific from $123.00 to $128.00 and gave the company an “outperform” rating in a report on Wednesday, October 1st. Evercore ISI reduced their price objective on shares of Boston Scientific from $115.00 to $110.00 and set an “outperform” rating for the company in a research note on Tuesday, October 7th. BTIG Research boosted their price objective on shares of Boston Scientific from $127.00 to $132.00 and gave the stock a “buy” rating in a report on Wednesday, October 1st. Finally, Raymond James Financial increased their target price on shares of Boston Scientific from $121.00 to $124.00 and gave the company a “strong-buy” rating in a report on Thursday, July 24th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, Boston Scientific currently has an average rating of “Buy” and an average price target of $120.71.

Insider Buying and Selling

In related news, Director Edward J. Ludwig sold 4,000 shares of the stock in a transaction on Friday, July 25th. The stock was sold at an average price of $106.03, for a total transaction of $424,120.00. Following the sale, the director owned 18,479 shares of the company’s stock, valued at $1,959,328.37. This trade represents a 17.79% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Yoshiaki Fujimori sold 2,901 shares of Boston Scientific stock in a transaction dated Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total value of $310,377.99. Following the sale, the director owned 2,081 shares of the company’s stock, valued at approximately $222,646.19. This represents a 58.23% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 174,214 shares of company stock worth $17,972,457 in the last 90 days. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Stock Performance

NYSE:BSX opened at $95.41 on Monday. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. The company has a market capitalization of $141.38 billion, a P/E ratio of 56.79, a price-to-earnings-growth ratio of 2.30 and a beta of 0.61. The firm has a 50-day moving average price of $101.98 and a two-hundred day moving average price of $101.87. Boston Scientific Corporation has a twelve month low of $80.64 and a twelve month high of $109.50.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating the consensus estimate of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The business had revenue of $5.06 billion for the quarter, compared to analyst estimates of $4.89 billion. During the same period in the prior year, the business earned $0.62 earnings per share. The company’s quarterly revenue was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, research analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.